The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas

Hyungjin Kim, Hyun Ju Lee, Hyunsook Hong, Young Jae Kim, Kwang Gi Kim, Yoon Kyung Jeon, Young Tae Kim

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: To investigate the prognostic impact of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement for the overall survival (OS) of patients with surgically treated lung adenocarcinomas. Methods: A total of 689 patients with stage I–III lung adenocarcinomas (male:female = 334:355; median age, 64 years) underwent complete surgical resection between 2007 and 2013. The prognostic impact of EGFR mutation and ALK rearrangement on OS was analyzed using Cox regression analysis. Certain clinicopathological prognostic factors (i.e., age, sex, smoking status, nodule type, solid portion size, pathologic stage, adenocarcinoma subtype, and history of adjuvant chemotherapy) were included for adjustments of the hazard ratio (HR). Results: EGFR mutation was observed in 438 patients (64%) and ALK rearrangement was seen in 28 patients (4%). Multivariable-adjusted Cox regression demonstrated that the prognostic effect of EGFR mutation on OS differed by age (HR, exp.[−5.199 + 0.064*age]). The adjusted HR for EGFR mutation was 0.14 (95% CI: 0.05–0.36; P < 0.001) at 50 years, 0.26 (95% CI: 0.15–0.46; P < 0.001) at 60 years, and 0.50 (95% CI: 0.31–0.81; P = 0.005) at 70 years. However, the effect of ALK rearrangement on OS was without statistical significance (P > 0.05). Conclusions: EGFR mutation was independently prognostic of the long-term outcomes of patients with surgically treated lung adenocarcinomas. A more favorable prognostic effect was seen in younger than in older patients. ALK rearrangement was not associated with OS.

Original languageEnglish
Pages (from-to)1619-1627
Number of pages9
JournalThoracic Cancer
Volume10
Issue number7
DOIs
StatePublished - 1 Jul 2019

Fingerprint

Epidermal Growth Factor Receptor
Mutation
Survival
Portion Size
Social Adjustment
Adjuvant Chemotherapy
anaplastic lymphoma kinase
Adenocarcinoma of lung
Adenocarcinoma
Smoking
Regression Analysis

Keywords

  • Adenocarcinoma
  • anaplastic lymphoma kinase
  • epidermal growth factor receptor
  • prognosis
  • survival analysis

Cite this

Kim, Hyungjin ; Lee, Hyun Ju ; Hong, Hyunsook ; Kim, Young Jae ; Kim, Kwang Gi ; Jeon, Yoon Kyung ; Kim, Young Tae. / The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas. In: Thoracic Cancer. 2019 ; Vol. 10, No. 7. pp. 1619-1627.
@article{1e2a5345537548528dc7d58374da3d76,
title = "The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas",
abstract = "Background: To investigate the prognostic impact of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement for the overall survival (OS) of patients with surgically treated lung adenocarcinomas. Methods: A total of 689 patients with stage I–III lung adenocarcinomas (male:female = 334:355; median age, 64 years) underwent complete surgical resection between 2007 and 2013. The prognostic impact of EGFR mutation and ALK rearrangement on OS was analyzed using Cox regression analysis. Certain clinicopathological prognostic factors (i.e., age, sex, smoking status, nodule type, solid portion size, pathologic stage, adenocarcinoma subtype, and history of adjuvant chemotherapy) were included for adjustments of the hazard ratio (HR). Results: EGFR mutation was observed in 438 patients (64{\%}) and ALK rearrangement was seen in 28 patients (4{\%}). Multivariable-adjusted Cox regression demonstrated that the prognostic effect of EGFR mutation on OS differed by age (HR, exp.[−5.199 + 0.064*age]). The adjusted HR for EGFR mutation was 0.14 (95{\%} CI: 0.05–0.36; P < 0.001) at 50 years, 0.26 (95{\%} CI: 0.15–0.46; P < 0.001) at 60 years, and 0.50 (95{\%} CI: 0.31–0.81; P = 0.005) at 70 years. However, the effect of ALK rearrangement on OS was without statistical significance (P > 0.05). Conclusions: EGFR mutation was independently prognostic of the long-term outcomes of patients with surgically treated lung adenocarcinomas. A more favorable prognostic effect was seen in younger than in older patients. ALK rearrangement was not associated with OS.",
keywords = "Adenocarcinoma, anaplastic lymphoma kinase, epidermal growth factor receptor, prognosis, survival analysis",
author = "Hyungjin Kim and Lee, {Hyun Ju} and Hyunsook Hong and Kim, {Young Jae} and Kim, {Kwang Gi} and Jeon, {Yoon Kyung} and Kim, {Young Tae}",
year = "2019",
month = "7",
day = "1",
doi = "10.1111/1759-7714.13128",
language = "English",
volume = "10",
pages = "1619--1627",
journal = "Thoracic Cancer",
issn = "1759-7706",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "7",

}

The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas. / Kim, Hyungjin; Lee, Hyun Ju; Hong, Hyunsook; Kim, Young Jae; Kim, Kwang Gi; Jeon, Yoon Kyung; Kim, Young Tae.

In: Thoracic Cancer, Vol. 10, No. 7, 01.07.2019, p. 1619-1627.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas

AU - Kim, Hyungjin

AU - Lee, Hyun Ju

AU - Hong, Hyunsook

AU - Kim, Young Jae

AU - Kim, Kwang Gi

AU - Jeon, Yoon Kyung

AU - Kim, Young Tae

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: To investigate the prognostic impact of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement for the overall survival (OS) of patients with surgically treated lung adenocarcinomas. Methods: A total of 689 patients with stage I–III lung adenocarcinomas (male:female = 334:355; median age, 64 years) underwent complete surgical resection between 2007 and 2013. The prognostic impact of EGFR mutation and ALK rearrangement on OS was analyzed using Cox regression analysis. Certain clinicopathological prognostic factors (i.e., age, sex, smoking status, nodule type, solid portion size, pathologic stage, adenocarcinoma subtype, and history of adjuvant chemotherapy) were included for adjustments of the hazard ratio (HR). Results: EGFR mutation was observed in 438 patients (64%) and ALK rearrangement was seen in 28 patients (4%). Multivariable-adjusted Cox regression demonstrated that the prognostic effect of EGFR mutation on OS differed by age (HR, exp.[−5.199 + 0.064*age]). The adjusted HR for EGFR mutation was 0.14 (95% CI: 0.05–0.36; P < 0.001) at 50 years, 0.26 (95% CI: 0.15–0.46; P < 0.001) at 60 years, and 0.50 (95% CI: 0.31–0.81; P = 0.005) at 70 years. However, the effect of ALK rearrangement on OS was without statistical significance (P > 0.05). Conclusions: EGFR mutation was independently prognostic of the long-term outcomes of patients with surgically treated lung adenocarcinomas. A more favorable prognostic effect was seen in younger than in older patients. ALK rearrangement was not associated with OS.

AB - Background: To investigate the prognostic impact of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement for the overall survival (OS) of patients with surgically treated lung adenocarcinomas. Methods: A total of 689 patients with stage I–III lung adenocarcinomas (male:female = 334:355; median age, 64 years) underwent complete surgical resection between 2007 and 2013. The prognostic impact of EGFR mutation and ALK rearrangement on OS was analyzed using Cox regression analysis. Certain clinicopathological prognostic factors (i.e., age, sex, smoking status, nodule type, solid portion size, pathologic stage, adenocarcinoma subtype, and history of adjuvant chemotherapy) were included for adjustments of the hazard ratio (HR). Results: EGFR mutation was observed in 438 patients (64%) and ALK rearrangement was seen in 28 patients (4%). Multivariable-adjusted Cox regression demonstrated that the prognostic effect of EGFR mutation on OS differed by age (HR, exp.[−5.199 + 0.064*age]). The adjusted HR for EGFR mutation was 0.14 (95% CI: 0.05–0.36; P < 0.001) at 50 years, 0.26 (95% CI: 0.15–0.46; P < 0.001) at 60 years, and 0.50 (95% CI: 0.31–0.81; P = 0.005) at 70 years. However, the effect of ALK rearrangement on OS was without statistical significance (P > 0.05). Conclusions: EGFR mutation was independently prognostic of the long-term outcomes of patients with surgically treated lung adenocarcinomas. A more favorable prognostic effect was seen in younger than in older patients. ALK rearrangement was not associated with OS.

KW - Adenocarcinoma

KW - anaplastic lymphoma kinase

KW - epidermal growth factor receptor

KW - prognosis

KW - survival analysis

UR - http://www.scopus.com/inward/record.url?scp=85067525244&partnerID=8YFLogxK

U2 - 10.1111/1759-7714.13128

DO - 10.1111/1759-7714.13128

M3 - Article

VL - 10

SP - 1619

EP - 1627

JO - Thoracic Cancer

JF - Thoracic Cancer

SN - 1759-7706

IS - 7

ER -